HomeMedical SpecialtiesGeriatrics and AgingBlood test can predict Alzheimer’s disease

Blood test can predict Alzheimer’s disease

Published on

A blood test that can predict with 90 per cent accuracy if a healthy person will develop mild cognitive impairment (MCI) or Alzheimer’s disease within three years has been discovered and validated by researchers at Georgetown University and six other institutions.

The study team explains in the April issue of Nature Medicine  how they discovered and then validated a set of 10 lipid biomarkers in the blood that predict both conditions.

The discovery heralds the possible development of earlier treatment options for Alzheimer’s, when therapy could be more effective at slowing or even preventing onset of the disease.

“Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder,” says the study’s corresponding author, Dr. Howard J. Federoff, executive vice president of health sciences at Georgetown University Medical Center.

There is currently no cure or effective treatment for Alzheimer’s disease, which, according to the World Health Organization, is expected to double every 20 years worldwide – from 35.6 million individuals in 2010 to 115.4 million by 2050.

Federoff, also a professor of neurology, explains there have been many efforts to develop drugs to slow or reverse the progression of Alzheimer’s disease, but all of them have failed. He says one reason may be the drugs were evaluated too late in the disease process.

“The preclinical state of the disease offers a window of opportunity for timely disease-modifying intervention, and biomarkers defining this asymptomatic period are critical for successful development and application of these therapeutics,” says Federoff.

‘Major Step Forward’

“The lipid panel was able to distinguish with 90 percent accuracy these two distinct groups – cognitively normal participants who would progress to MCI or AD within two to three years, and those who would remain normal in the near future,” says Federoff, who also serves as executive dean of the School of Medicine.

Researchers say the panel reveals changes in the breakdown of neural cell membranes resulting in 10 identifiable lipids, or metabolites, circulating in the blood. In particular, two of the 10 metabolites have strong links to the neuropathology of Alzheimer’s.

“We consider our results a major step toward the commercialization of a preclinical disease biomarker test that could be useful for large-scale screening to identify at-risk individuals,” Federoff concludes. “We’re intending to design a clinical trial where we’ll use this panel to identify people at high risk for Alzheimer’s to test a therapeutic agent that might delay or prevent the emergence of the disease.”

Latest articles

An ER doctor’s experience with long COVID – “My symptoms seemed endless”

On April 2022, another COVID wave was sweeping Toronto. It was the sixth since...

Tackling the issue of unused medication waste

When patients and programs don’t use all the medication that is prescribed, it is...

Obesity a risk factor for stillbirth, especially at term

Obesity is a risk factor for stillbirth, and the risk increases as pregnancy advances...

Prolonged cough? In most cases, patience is the treatment

Coughing after a respiratory infection is common and, in most cases, will resolve with...

More like this

Tackling the issue of unused medication waste

When patients and programs don’t use all the medication that is prescribed, it is...

Yukon Home Care embraces e-bikes for service delivery

Working collaboratively with other government departments, First Nations governments, medical facilities and community partners,...

Funding to take LHSC developed technology global

On average it takes five to seven years to diagnose a rare disease. But,...

Surgical guidance with AI

Researchers at UHN’s Toronto General Hospital Research Institute (TGHRI) have utilized artificial intelligence (AI)...

Navigating the fallout: 23andMe’s data breach and the ethics of consumer genetic testing

By unlocking secrets encrypted within our DNA, genetic testing has become a powerful tool,...

Testing new technology to help older adults age at home

When 72-year-old Hamilton resident Shirley was asked if she’d be interested in participating in...